Abstract:        Obesity, a growing global issue, has been closely associated with an increased risk of various cancers, especially breast cancer. El ...

Lemon balm is no magic pill, but its effects, including better stress regulation and blood sugar control, may support factors ...

Four clinical organizations jointly release an advisory with evidence-based nutrition and lifestyle interventions to enhance ...

Primary care physicians aren’t quick to diagnose lymphedema in patients with obesity, a situation that needs to change, ...

Consuming certain spices, such as chili pepper, turmeric, ginger, and cinnamon, may positively affect metabolism and help ...

Pancreatic cancer is one of the deadliest forms of cancer, killing 87% of patients within five years. Previous studies have ...

For adults with diabetes and obesity, GLP-1 RAs are associated with a reduced risk for obesity-related cancer compared with DPP-4 inhibitors.

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...